Recent investigations have revealed that mutations in PIK3CA deliberate sensitivity to AKT targeted therapy in bladder cancer by regulating DUSP1 expression and subsequent ERK1/2 dephosphorylation and can potentially serve as a stratifying biomarker for treatment (Sathe et al., 2014[39]). The gene discussed is AKT1; the disease is urinary bladder carcinoma.